2013-07-18 | Libourne
Libourne, France, July 18, 2013 - Ceva Santé Animales S.A. today signed a definitive agreement to acquire a controlling stake in Sichuan Hengtong's animal health subsidiary - Sichuan Hengtong Animal Health Biotechnology Co., Ltd in China. E. J. McKay acted as the exclusive financial advisor to CEVA. The transaction will allow CEVA to significantly increase its business scope in China, especially in the swine animal health segment. Representatives from the Chinese Embassy in Paris and the French Ministry of Foreign Trade also attended the signing ceremony in Libourne, situated in the famed Bordeaux region.
"We are very pleased to have advised and represented CEVA in this transaction," E. J. McKay CEO James Z. Li commented. "It will not only strengthen CEVA's market-leading position worldwide, but also create a positive impact on the veterinary health industry and food security in China. This transaction also demonstrates E. J. McKay's leadership in the pharmaceutical sector and our commitment to the France-China investment corridor."
Headquartered in Libourne, France, CEVA is among the top 10 largest animal health groups globally, with expertise in pharmacology and biology and dedicated teams focused on the companion animal, poultry, ruminant, and swine sectors. Spun-off from Sanofi-Aventis in 1999, the company has been invested by leading investment firms PAI Partners, Industri Kapital, Euromezzanine, and Natixis Private Equity. Today, CEVA is directly present in 42 countries, with 13 research and development centers, and 21 production sites. See www.ceva.com for more details.
Sichuan Hengtong's animal health subsidiary - Sichuan Hengtong Animal Health Biotechnology Co., Ltd, located in Sichuan Province, China, is a leading player in Chinese veterinary pharmaceutical market. The company has full country coverage, providing powder injection, liquid injection, powder, tablet, oral liquid, and premix animal health pharmaceuticals.